company background image
KRON

Kronos BioNasdaqGS:KRON Stock Report

Market Cap

US$960.3m

7D

5.1%

1Y

-43.1%

Updated

26 Oct, 2021

Data

Company Financials +
KRON fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

KRON Overview

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics.

Price History & Performance

Summary of all time highs, changes and price drops for Kronos Bio
Historical stock prices
Current Share PriceUS$17.07
52 Week HighUS$15.86
52 Week LowUS$39.61
Beta0
1 Month Change-29.38%
3 Month Change-20.79%
1 Year Change-43.10%
3 Year Changen/a
5 Year Changen/a
Change since IPO-36.94%

Recent News & Updates

Mar 03
How Much Of Kronos Bio, Inc. (NASDAQ:KRON) Do Insiders Own?

How Much Of Kronos Bio, Inc. (NASDAQ:KRON) Do Insiders Own?

If you want to know who really controls Kronos Bio, Inc. ( NASDAQ:KRON ), then you'll have to look at the makeup of its...

Shareholder Returns

KRONUS BiotechsUS Market
7D5.1%1.5%0.9%
1Y-43.1%17.8%33.4%

Return vs Industry: KRON underperformed the US Biotechs industry which returned 18.8% over the past year.

Return vs Market: KRON underperformed the US Market which returned 33.4% over the past year.

Price Volatility

Is KRON's price volatile compared to industry and market?
KRON volatility
KRON Beta0
Industry Beta0.98
Market Beta1

Stable Share Price: KRON is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: KRON's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201790Norbert Bischofbergerhttps://kronosbio.com

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company’s product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients.

Kronos Bio Fundamentals Summary

How do Kronos Bio's earnings and revenue compare to its market cap?
KRON fundamental statistics
Market CapUS$960.26m
Earnings (TTM)-US$128.01m
Revenue (TTM)n/a

0x

P/S Ratio

-7.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
KRON income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$128.01m
Earnings-US$128.01m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-2.28
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did KRON perform over the long term?

See historical performance and comparison

Valuation

Is Kronos Bio undervalued compared to its fair value and its price relative to the market?

2.26x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate KRON's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate KRON's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: KRON is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: KRON is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate KRON's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: KRON is good value based on its PB Ratio (2.3x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is Kronos Bio forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

-16.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: KRON is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KRON is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KRON is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KRON is forecast to have no revenue next year.

High Growth Revenue: KRON is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if KRON's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Kronos Bio performed over the past 5 years?

-411.0%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: KRON is currently unprofitable.

Growing Profit Margin: KRON is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if KRON's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare KRON's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KRON is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: KRON has a negative Return on Equity (-30.18%), as it is currently unprofitable.


Financial Health

How is Kronos Bio's financial position?


Financial Position Analysis

Short Term Liabilities: KRON's short term assets ($424.3M) exceed its short term liabilities ($13.1M).

Long Term Liabilities: KRON's short term assets ($424.3M) exceed its long term liabilities ($34.6M).


Debt to Equity History and Analysis

Debt Level: KRON is debt free.

Reducing Debt: KRON had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KRON has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: KRON has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 74% each year.


Dividend

What is Kronos Bio current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate KRON's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate KRON's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if KRON's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KRON's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of KRON's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Norbert Bischofberger (65 yo)

3.17yrs

Tenure

US$15,152,793

Compensation

Dr. Norbert W. Bischofberger, Ph D., is Director of Morphic Holding, Inc. since June 14, 2019. Dr. Bischofberger serves as a Director of Kronos Bio, Inc. since April 2018.He joined Kronos Bio in 2018 and...


CEO Compensation Analysis

Compensation vs Market: Norbert's total compensation ($USD15.15M) is above average for companies of similar size in the US market ($USD2.25M).

Compensation vs Earnings: Norbert's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: KRON's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: KRON's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: KRON insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.2%.


Top Shareholders

Company Information

Kronos Bio, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Kronos Bio, Inc.
  • Ticker: KRON
  • Exchange: NasdaqGS
  • Founded: 2017
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$960.259m
  • Shares outstanding: 56.25m
  • Website: https://kronosbio.com

Number of Employees


Location

  • Kronos Bio, Inc.
  • 1300 South El Camino Real
  • Suite 300
  • San Mateo
  • California
  • 94402
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/26 22:44
End of Day Share Price2021/10/26 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.